Prognostic factors in pulmonary metastasectomy: Spotlight on molecular and radiological markers

European Journal of Cardio-thoracic Surgery

Volumn 45, Issue 3, 2014, Pages 408-416

  Schweiger, Thomas ^a   Lang, György ^a   Klepetko, Walter ^a   Hoetzenecker, Konrad ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Lung metastasis; Molecular biology; Prognostic marker; Pulmonary metastasectomy; Radiology

Indexed keywords

TUMOR MARKER; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

HUMAN; LUNG NEOPLASMS; LUNG RESECTION; METABOLISM; METASTASIS RESECTION; PROGNOSIS; RADIOGRAPHY;

HUMANS; LUNG NEOPLASMS; METASTASECTOMY; NEOPLASM PROTEINS; PNEUMONECTOMY; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84894337730     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezt288     Document Type: Review

References (79)

1. Weinlechner J. Zur Kasuistik der Tumoren der Brustwand und deren Behandlung (Resektion der Rippen, Eröffnung der Brusthöhle, partielle Entfernung der Lunge).Wien Med Wochenschr 1882;32:589-91.
2. Monteiro A, Arce N, Bernardo J, Eugenio L, Antunes MJ. Surgical resection of lung metastases from epithelial tumors. Ann Thorac Surg 2004;77: 431-7.
3. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J Thorac Cardiovasc Surg 1997;113:37-49.
4. Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg 2007;84:324-38.
5. Gonzalez M, Poncet A, Combescure C, Robert J, Ris HB, Gervaz P. Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol 2012;20:572-79.
6. Kanemitsu Y, Kato T, Hirai T, Yasui K. Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer. Br J Surg 2004;91:112-20.
7. Verberne CJ, Wiggers T, Vermeulen KM, de Jong KP. Detection of recurrences during follow-up after liver surgery for colorectal metastases: both carcinoembryonic antigen (CEA) and imaging are important. Ann Surg Oncol 2012;20:475-63.
8. Iida T, Nomori H, Shiba M, Nakajima J, Okumura S, Horio H et al. Prognostic factors after pulmonary metastasectomy for colorectal cancer and rationale for determining surgical indications: a retrospective analysis. Ann Surg 2012;257:1059-64.
9. Salah S, Watanabe K, Welter S, Park JS, Park JW, Zabaleta J et al. Colorectal cancer pulmonary oligometastases: pooled analysis and construction of a clinical lung metastasectomy prognostic model. Ann Oncol 2012;23: 2649-55.
10. Kayser K, Zink S, Andre S, Schuring MP, Hecker E, Klar E et al. Primary colorectal carcinomas and their intrapulmonary metastases: clinical, glyco-, immuno-and lectin histochemical, nuclear and syntactic structure analysis with emphasis on correlation with period of occurrence of metastases and survival. Apmis 2002;110:435-46.
11. Nakagawa T, Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Matsushita M et al. Pulmonary resection for metastases from hepatocellular carcinoma: factors influencing prognosis. J Thorac Cardiovasc Surg 2006;131: 1248-54.
12. Ohba T, Yano T, Yoshida T, Kawano D, Tsukamoto S, Shoji F et al. Results of a surgical resection of pulmonary metastasis from hepatocellular carcinoma: prognostic impact of the preoperative serum alpha-fetoprotein level. Surg Today 2012;42:526-31.
13. Kuo SW, Chang YL, Huang PM, Hsu HH, Chen JS, Lee JM et al. Prognostic factors for pulmonary metastasectomy in hepatocellular carcinoma. Ann Surg Oncol 2007;14:992-7.
14. Kitano K, Murayama T, Sakamoto M, Nagayama K, Ueno K, Murakawa T et al. Outcome and survival analysis of pulmonary metastasectomy for hepatocellular carcinoma. Eur J Cardiothorac Surg 2012;41:376-82.
15. Pfannschmidt J, Zabeck H, Muley T, Dienemann H, Hoffmann H. Pulmonary metastasectomy following chemotherapy in patients with testicular tumors: experience in 52 patients. Thorac Cardiovasc Surg 2006;54: 484-8.
16. Boveri T. Zur Frage der Entstehung maligner Tumoren. Jena: G. Fischer, 1914.
17. Gao D, Vahdat LT, Wong S, Chang JC, Mittal V. Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res 2012;72: 4883-9.
18. Shiono S, Ishii G, Nagai K, Yoshida J, Nishimura M, Murata Y et al. Histopathologic prognostic factors in resected colorectal lung metastases. Ann Thorac Surg 2005;79:278-82; discussion 83.
19. Shiono S, Ishii G, Nagai K, Yoshida J, Nishimura M, Murata Y et al. Predictive factors for local recurrence of resected colorectal lung metastases. Ann Thorac Surg 2005;80:1040-5.
20. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1994;1198:11-26.
21. Shiono S, Ishii G, Nagai K, Murata Y, Tsuta K, Nitadori J et al. Immunohistochemical prognostic factors in resected colorectal lung metastases using tissue microarray analysis. Eur J Surg Oncol 2006;32:308-9.
22. Tsukada M, Wakai T, Matsuda Y, Korita PV, Shirai Y, Ajioka Y et al. Loss of carcinoembryonic antigen-related cell adhesion molecule 1 expression predicts metachronous pulmonary metastasis and poor survival in patients with hepatoblastoma. J Pediatr Surg 2009;44:1522-8.
23. Cruz PV, Wakai T, Shirai Y, Yokoyama N, Hatakeyama K. Loss of carcinoembryonic antigen-related cell adhesion molecule 1 expression is an adverse prognostic factor in hepatocellular carcinoma. Cancer 2005;104:354-60.
24. Jaggupilli A, Elkord E. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol 2012;2012:708036.
25. Jacobs PP, Sackstein R. CD44 and HCELL: preventing hematogenous metastasis at step 1. FEBS Lett 2011;585:3148-58.
26. Kim SH, Choi SJ, Cho YB, Kang MW, Lee J, Lee WY et al. Differential gene expression during colon-to-lung metastasis. Oncol Rep 2011;25:629-36.
27. Goi T, Koneri K, Katayama K, Hirose K, Yamaguchi A. Evaluation of clinicopathological factors and the correlation between the adhesion molecule CD44 variant 9 expression and pulmonary metastases from colorectal cancers. Int Surg 2002;87:130-6.
28. Indinnimeo M, Cicchini C, Giarnieri E, Stazi A, Mingazzini PL, Stipa V. Evaluation of CD44 variant 6 expression and clinicopathological factors in pulmonary metastases from colon carcinoma. Oncol Rep 2003;10:1875-7.
29. Rambaruth ND, Dwek MV. Cell surface glycan-lectin interactions in tumor metastasis. Acta Histochem 2011;113:591-600.
30. Sato T, Konishi K, Maeda K, Yabushita K, Miwa A. Integrin alpha v, c-erbB2 and DNA ploidy in lung metastases from colorectal cancer. Hepatogastroenterology 2003;50:27-30.
31. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
32. Hernandez-Rodriguez NA, Correa E, Sotelo R, Contreras-Paredes A, Gomez-Ruiz C, Green L et al. Ki-67: a proliferative marker that may predict pulmonary metastases and mortality of primary osteosarcoma. Cancer Detect Prev 2001;25:210-5.
33. Oda Y, Yamamoto H, Tamiya S, Matsuda S, Tanaka K, Yokoyama R et al. CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol 2006;19:738-45.
34. Lee JH, Gulec SA, Kyshtoobayeva A, Sim MS, Morton DL. Biological factors, tumor growth kinetics, and survival after metastasectomy for pulmonary melanoma. Ann Surg Oncol 2009;16:2834-9.
35. Gotoh A, Hanioka K, Shirakawa T, Wada Y, Gohji K, Okada H et al. Assessment of proliferating cell nuclear antigen expression and prognosis in patients with renal cell carcinoma with pulmonary metastases. Int J Urol 1998;5:214-8.
36. Valera V, Yokoyama N, Walter B, Okamoto H, Suda T, Hatakeyama K. Clinical significance of Ki-67 proliferation index in disease progression and prognosis of patients with resected colorectal carcinoma. Br J Surg 2005; 92:1002-7.
37. Lumachi F, Orlando R, Marino F, Chiara GB, Basso SM. Expression of p53 and Ki-67 as prognostic factors for survival of men with colorectal cancer. Anticancer Res 2012;32:3965-7.
38. Chojniak R, Younes RN. Pulmonary metastases tumor doubling time: assessment by computed tomography. Am J Clin Oncol 2003;26: 374-7.
39. Sadahiro S, Suzuki T, Ishikawa K, Nakamura T, Tanaka Y, Ishizu K et al. Estimation of the time of pulmonary metastasis in colorectal cancer patients with isolated synchronous liver metastasis. Jpn J Clin Oncol 2005; 35:18-22.
40. Tomimaru Y, Noura S, Ohue M, Okami J, Oda K, Higashiyama M et al. Metastatic tumor doubling time is an independent predictor of intrapulmonary recurrence after pulmonary resection of solitary pulmonary metastasis from colorectal cancer. Dig Surg 2008;25:220-5.
41. Blomqvist C, Wiklund T, Tarkkanen M, Elomaa I, Virolainen M. Measurement of growth rate of lung metastases in 21 patients with bone or soft-tissue sarcoma. Br J Cancer 1993;68:414-7.
42. Roth JA, Putnam JB Jr, Wesley MN, Rosenberg SA. Differing determinants of prognosis following resection of pulmonary metastases from osteogenic and soft tissue sarcoma patients. Cancer 1985;55:1361-6.
43. Nakamura T, Matsumine A, Matsubara T, Asanuma K, Uchida A, Sudo A. Clinical impact of the tumor volume doubling time on sarcoma patients with lung metastases. Clin Exp Metastasis 2011;28:819-25.
44. Ollila DW, Stern SL, Morton DL. Tumor doubling time: a selection factor for pulmonary resection of metastatic melanoma. J Surg Oncol 1998;69: 206-11.
45. Ferrari S, Bertoni F, Zanella L, Setola E, Bacchini P, Alberghini M et al. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer 2004;100:1936-42.
46. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009;9:489-99.
47. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323-31.
48. Danner BC, Gerdes JS, Jung K, Sander B, Enders C, Liersch T et al. Comparison of chromosomal aberrations in primary colorectal carcinomas to their pulmonary metastases. Cancer Genet 2011;204:122-8.
49. Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999;17:2781-8.
50. Diep CB, Kleivi K, Ribeiro FR, Teixeira MR, Lindgjaerde OC, Lothe RA. The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes. Genes Chromosomes Cancer 2006;45:31-41.
51. Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K et al. Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Dis Colon Rectum 2011;54:1170-8.
52. Kim MJ, Lee HS, Kim JH, Kim YJ, Kwon JH, Lee JO et al. Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer 2012; 12:347.
53. Tie J, Lipton L, Desai J, Gibbs P, Jorissen RN, Christie M et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res 2011;17:1122-30.
54. Cejas P, Lopez-Gomez M, Aguayo C, Madero R, de Castro Carpeno J, Belda-Iniesta C et al. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One 2009;4:e8199.
55. Welter S, Jacobs J, Krbek T, Totsch M, Stamatis G. Pulmonary metastases of breast cancer. When is resection indicated? Eur J Cardiothorac Surg 2008; 34:1228-34.
56. Akatsuka T, Wada T, Kokai Y, Kawaguchi S, Isu K, Yamashiro K et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 2002;94:1397-404.
57. Onda M, Matsuda S, Higaki S, Iijima T, Fukushima J, Yokokura A et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 1996;77:71-8.
58. Zhou H, Randall RL, Brothman AR, Maxwell T, Coffin CM, Goldsby RE. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol 2003;25:27-32.
59. Magrisso IJ, Richmond RE, Carter JH, Pross CB, Gilfillen RA, Carter HW. Immunohistochemical detection of RAS, JUN, FOS, and p53 oncoprotein expression in human colorectal adenomas and carcinomas. Lab Invest 1993;69:674-81.
60. Pfannschmidt J, Bade S, Hoheisel J, Muley T, Dienemann H, Herpel E. Identification of immunohistochemical prognostic markers for survival after resection of pulmonary metastases from colorectal carcinoma. Thorac Cardiovasc Surg 2009;57:403-8.
61. Sato T, Miwa A. Ets-1 and integrin beta3 for lung metastasis from colorectal cancer. Apmis 2002;110:347-53.
62. Warburg O. Note on the metabolism of tumours. Biochem Z 1930;228: 257-8.
63. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891-9.
64. Riedl CC, Akhurst T, Larson S, Stanziale SF, Tuorto S, Bhargava A et al. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med 2007;48:771-5.
65. Kaira K, Okumura T, Ohde Y, Takahashi T, Murakami H, Oriuchi N et al. Correlation between 18F-FDG uptake on PET and molecular biology in metastatic pulmonary tumors. J Nucl Med 2011;52:705-11.
66. Jensen NF, Smith DH, Nygard SB, Romer MU, Nielsen KV, Brunner N. Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer. Scand J Gastroenterol 2012;47:340-55.
67. Yamada H, Ichikawa W, Uetake H, Shirota Y, Nihei Z, Sugihara K et al. Thymidylate synthase gene expression in primary colorectal cancer and metastatic sites. Clin Colorectal Cancer 2001;1:169-73; discussion 74.
68. Gorlick R, Metzger R, Danenberg KD, Salonga D, Miles JS, Longo GS et al. Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. J Clin Oncol 1998;16:1465-9.
69. Cascinu S, Aschele C, Barni S, Debernardis D, Baldo C, Tunesi G et al. Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorinmodulated bolus 5-fluorouracil. Clin Cancer Res 1999;5:1996-9.
70. Kaira K, Okumura T, Ohde Y, Takahashi T, Murakami H, Kondo H et al. Prognostic significance of thymidylate synthase expression in the adjuvant chemotherapy after resection for pulmonary metastases from colorectal cancer. Anticancer Res 2011;31:2763-71.
71. Bradshaw DM, Arceci RJ. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 1998;16:3674-90.
72. Romano M, Claria J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J 2003;17:1986-95.
73. Milas L, Mason KA, Crane CH, Liao Z, Masferrer J. Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme. Oncology 2003;17:15-24.
74. Rodriguez NI, Hoots WK, Koshkina NV, Morales-Arias JA, Arndt CA, Inwards CY et al. COX-2 expression correlates with survival in patients with osteosarcoma lung metastases. J Pediatr Hematol Oncol 2008;30:507-12.
75. Dickens DS, Kozielski R, Leavey PJ, Timmons C, Cripe TP. Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma. J Pediatr Hematol Oncol 2003;25:282-5.
76. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011;17:1359-70.
77. Muehling BM, Toelkes S, Schelzig H, Barth TF, Sunder-Plassmann L. Tyrosine kinase expression in pulmonary metastases and paired primary tumors. Interact CardioVasc Thorac Surg 2010;10:228-31.
78. Simone G, Mangia A, Malfettone A, Rubini V, Siciliano M, Di Benedetto A et al. Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer. J Exp Clin Cancer Res 2010; 29:125.
79. Tamura M, Oda M, Tsunezuka Y, Matsumoto I, Kawakami K, Watanabe G. Vascular endothelial growth factor expression in metastatic pulmonary tumor from colorectal carcinoma: utility as a prognostic factor. J Thorac Cardiovasc Surg 2004;128:517-22.